HOSPITAL UNIVERSITARIO RUBER
Fachbereich
University Hospital Heidelberg
Heidelberg, AlemaniaPublikationen in Zusammenarbeit mit Forschern von University Hospital Heidelberg (17)
2023
-
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Cancer Research Communications, Vol. 3, Núm. 9, pp. 1853-1861
-
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
The oncologist, Vol. 28, Núm. 1, pp. 23-32
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial
JAMA Oncology, Vol. 7, Núm. 12, pp. 1791-1799
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530
2019
-
Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA Substudy
Journal of the National Cancer Institute, Vol. 111, Núm. 1
2018
-
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
European Journal of Cancer, Vol. 89, pp. 27-35
-
Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic Breast cancer: Results from the tnAcity trial
Annals of Oncology, Vol. 29, Núm. 8, pp. 1763-1770
-
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859
2017
-
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Annals of Oncology, Vol. 28, Núm. 4, pp. 761-768
2016
-
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts
Critical Reviews in Oncology/Hematology, Vol. 99, pp. 81-90
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710
-
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
New England Journal of Medicine, Vol. 372, Núm. 8, pp. 724-734
2014
2013
-
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
Annals of Oncology, Vol. 24, Núm. 9, pp. 2278-2284
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 14, Núm. 6, pp. 461-471